Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.53), $0.21 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $0 versus the consensus estimate of $3.79 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.